This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2007 by Saitama Medical University.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Non-Profit Organaizaion "LINE"
Information provided by:
Saitama Medical University
ClinicalTrials.gov Identifier:
NCT00288717
First received: February 7, 2006
Last updated: January 9, 2007
Last verified: January 2007
  Purpose
To investigate the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid-metabolism in the hypertensive patients with the accumulation of visceral fat by the newly developed Tele-medicine system

Condition Intervention
Hypertension Drug: Candesartan Drug: Telmisartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System

Resource links provided by NLM:


Further study details as provided by Saitama Medical University:

Primary Outcome Measures:
  • Home blood pressure in the early morning

Secondary Outcome Measures:
  • Home blood pressure at bedtime
  • M/E ratio
  • Casual blood pressure
  • Body fat percentage
  • Body weight
  • Height
  • BMI
  • Blood potassium
  • Total cholesterol
  • HDL cholesterol
  • LDL cholesterol
  • Triglyceride
  • Blood glucose
  • IRI
  • HbAlc*
  • HOMA-IR
  • Urinary trace albumin
  • Creatinine

Estimated Enrollment: 300
Study Start Date: February 2006
Estimated Study Completion Date: September 2007
Detailed Description:
A randomized, comparative study of the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid metabolism in the hypertensive patients with the accumulation of visceral fat by the central registration system
  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Circumference at waist: male ≧85 cm, female ≧90 cm
  • Hypertensive patient with untreated hypertension, and casual blood pressure of systole ≧140 mmHg, or diastole ≧90 mmHg
  • Hypertensive patient with hypertension under treatment, and casual blood pressure of systole ≧130 mmHg, or diastole ≧85 mmHg

Exclusion Criteria:

  • Significant hypertensive patient with diastolic blood pressure ≧120 mmHg
  • Malignant hypertensive patient
  • Patient with a contraindication to the study drugs (hypersensitivity, significant hepatic diseases, pregnant woman)
  • Patient with urinary protein (qualitative) +~++
  • Patient with familial hyperlipidemia
  • Other patients judged as ineligible for the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00288717

Contacts
Contact: Hidetomo Nakamoto, MD +81-0492-76-1258 nakamo_h@saitama-med.ac.jp

Locations
Japan
Saitama Medical School Department of Renal Medicine Recruiting
Saitama City, Saitama, Japan, 350-0495
Contact: Hidetomo Nakamoto, MD    +81-492-76-1258    nakamo_h@saitama-med.ac.jp   
Principal Investigator: Hidetomo Nakamoto, MD         
Sponsors and Collaborators
Saitama Medical University
Non-Profit Organaizaion "LINE"
Investigators
Principal Investigator: Hidetomo Nakamoto, MD Saitama Medical School Department of Renal Medicine
  More Information

ClinicalTrials.gov Identifier: NCT00288717     History of Changes
Other Study ID Numbers: FUJIYAMA-Study
UMIN-CTR-C000000324
Study First Received: February 7, 2006
Last Updated: January 9, 2007

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Telmisartan
Candesartan
Candesartan cilexetil
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 22, 2017